The Effect of High-dose Remifentanil on the Reversal of Neuropathic Pain in Postherpetic Patients - RemiHighDose PHZ
- Conditions
- Post herpetic hyperalgesia
- Registration Number
- EUCTR2010-020042-94-AT
- Lead Sponsor
- Medizinische Universität Wien, Universitätsklinik für Anästhesie, Allgemeine Intensivmedizin
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 21
•Patients suffering from PHN.
•Pain = 4 out of 10 in numeric rating scale (NRS)
•Female and male patients above the age of 18
•Ability to understand/write/read german
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
•Any of the following will exclude a subject from the study:
•Zoster affecting trigeminal-, opticus region
•Any somatic pain which is stronger than the neuropathic pain
•Severe progressive disease
•Acute cardiac decompensation
•Known cardiac valve dysfunction
•Known pulmonary hypertension
•Cardiac conduction disturbance
•Active herpetic lesion
•Analgesic or antitussive opioid therapy
•Bronchial asthmal
•Known chronic obstructive pulmonary disease (COPD) >GOLD II
•Severe psychiatric condition
•Abuse of alcoholic beverages, drug abuse
•Negative neuropathic symptoms
•Pregnancy or breast feeding
•Participation in a clinical trial in the 2 weeks preceding the study
•Allergy against any medication used in the study protocol
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method